A randomized trial of propofol versus midazolam of sedation during radio frequency ablation in patients with hepatocellular carcinoma

A randomized trial of propofol versus midazolam of sedation during radio frequency ablation in patients with hepatocellular carcinoma - A randomized trial of propofol versus midazolam of sedation during radio frequency ablation in patients with hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011443

Enrollment

140

Registered

2013-08-10

Start date

2013-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

propofol of sedation midazolam of sedation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 20 years-old (Gender does not matter). 2) Acquisition of written informed consent. 3) Have been diagnosed with hepatocellular carcinoma. 4)ECOG performance status of 0-1. 5) Child-Pugh A or B. 6) Among patients who fulfill the inclusion criteria.

Exclusion criteria

Exclusion criteria: 1)Patients with sever cardiovascular disorder 2)American Society of Anesthesiologists (ASA) : 4 or more 3)Body Mass Index (BMI): 30 or more 4)Patients who knwn cotraindications for propfol pr midazolam

Design outcomes

Primary

Measure	Time frame
patient's degree of satisfaction	—

Countries

Japan

Contacts

Public ContactSadahisa Ogasawara

Chiba university hospital Department of Gastroenterology

sadahisa@me.com043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026